Disruption of differentiation in human cancer: AML shows the way

Nature Reviews Cancer

Volumn 3, Issue 2, 2003, Pages 89-101

  Tenen, Daniel G ^a  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; LEUCINE ZIPPER PROTEIN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; AML1 GENE; CELL DIFFERENTIATION; CELL TRANSFORMATION; GENE; GENE MUTATION; HEMATOPOIESIS; HETEROZYGOSITY LOSS; HUMAN; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION; ACUTE GRANULOCYTIC LEUKEMIA; GENETICS; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

CELL DIFFERENTIATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MUTATION; NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 0037315894     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc989     Document Type: Review

References (125)

1. Nichols, J. & Nimer, S. D. Transcription factors, translocations, and leukemia. Blood 80, 2953-2983 (1992).
2. Till, J. E. & McCulloch, E. A. Hemopoietic stem cell differentiation. Biochim. Biophys. Acta 605, 431-459 (1980).
3. Ogawa, M. Differentiation and proliferation of hematopoietic stem cells. Blood 81, 2844-2853 (1993).
4. Spangrude, G. J., Heimfeld, S. & Weissman, I. L. Purification and characterization of mouse hematopoietic stem cells. Science 241, 58-62 (1988).
5. Akashi, K., Traver, D., Miyamoto, T. & Weissman, I. L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193-197 (2000). Describes the methodology for isolation and analysis of progenitors at precisely defined functional stages of differentiation.
6. Miyamoto, T. et al. Myeloid or lymphoid promiscuity as a cntical step in hematopoietic lineage commitment. Dev. Cell 3, 137-147 (2002).
7. Yuan, Y. et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc. Natl Acad. Sci. USA 98, 10398-10403 (2001).
8. Shivdasani, R. A. & Orkin, S. H. The transcriptional control of hematopoiesis. Blood 87, 4025-4039 (1996).
9. Tenen, D. G., Hromas, R., Licht, J. D. & Zhang, D.-E. Transcription factors, normal myeloid development, and leukemia. Blood 90, 489-519 (1997).
10. Tenen, D. G. Hematopoiesis (ed. Zon, L. I.) 417-428 (Oxford University Press, New York, 2001).
11. Burel, S.A. et al. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol. Cell. Biol. 21, 5577-5590 (2001).
12. De Guzman, C. G. et al. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol. Cell. Biol. 22, 5508-5517 (2002).
13. Speck, N. A. & Gilliland, D. G. Core-binding factors in haematopoiesis and leukaemia. Nature Rev. Cancer 2, 502-513 (2002).
14. Nuclfora, G. & Rowley, J. D. AML1 and the 8:21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 86, 1-14 (1995).
15. Huang, G. et al. Dimerization with PEBP2β protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 20, 723-733 (2001).
16. Orkin, S. H. Diversification of haematopoietic stem cells to specific lineages. Nature Rev. Genet. 1, 57-64 (2000).
17. Rekhtman, N., Radparvar, F., Evans, T. & Skouitchi, A. I. Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Genes Dev. 13, 1398-1411 (1999).
18. Zhang, P. et al. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc. Natl Acad. Sci. USA 96, 8705-8710 (1999).
19. Nerlov, C., Querfurth, E., Kulessa, H. & Graf, T. GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1 dependent transcription. Blood 95, 2543-2551 (2000).
20. Nerlov, C., Tenen, D. G. & Graf, T. Hematopoiesis: A Developmental Approach (ed. Zon, L. I) 363-367 (Oxford University Press, New York, 2001).
21. Mcdevitt, M. A., Shivdasani, R. A., Fujiwara, Y., Yang, H. D. & Orkin, S. H. A 'knockdown' mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc. Natl Acad. Sci. USA 94, 6781-6785 (1997).
22. Cantor, A. B., Katz, S. G. & Orkin, S. H. Distinct domains of the GATA-1 cofactor FOG-1 differentially influence erythroid versus megakaryocytic maturation. Mol. Cell. Biol. 22, 4268-4279 (2002).
23. Zhang, D.-E. et al. Molecular Aspects of Myeloid Stem Cell Development (eds Wolff, L. & Perkins, A. S.) 137-147 (Springer, Heidelberg, 1996).
24. Tenen, D. G. Transcription Factors: Normal and Malignant Development of Blood Cells (eds Ravid, K. & Ucht, J.) 103-115 (Wiley & Sons, New York, 2001).
25. Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G. & Downing, J. R. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84, 321-330 (1996).
26. Wang, Q. et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoesis. Proc. Natl Acad. Sci. USA 93, 3444-3449 (1996).
27. Scott, E. W., Simon, M. C., Anastai, J. & Singh, H. The transcnption factor PU.1 is required for the development of multiple hematopoietic lineages. Science 265, 1573-1577 (1994).
28. McKercher, S. R. et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 15, 5647-5658 (1996).
29. DeKoter, R. P., Walsh, J. C. & Singh, H. PU.1 regulates both cytokine dependent proliferation and differentiation of granulocyte/macrophage progenitors. EMBO J. 17, 4456-4468 (1998). Shows that PU.1-deficient cells are blocked at an early stage of myeloid maturation, and that introduction of PU.1 (but not cytokine signalling) restores differentiation.
30. Anderson, K. L. et al. PU.1 and the granulocyte- and macrophage colony-stimulating factor receptors play distinct roles in late-stage myeloid cell differentiation. Blood 94, 2310-2318 (1999).
31. Reddy, V. et al. The granulocytic inducer C/EBPα inactivates the myeloid master gene PU.1: possible role in lineage commitment decisions. Blood 100, 483-490 (2002).
32. Radomska, H. S. et al. CCAAT/enhancer binding protein-α is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol. Cell. Biol. 18, 4301-4314 (1998).
33. Zhang, P. et al. C/EBPα deficiency blocks granulocytic differentiation at the common myeloid progenitor stage in both adult and fetal liver myelopoiesis. Blood 98, 792a (2001).
34. Hohaus, S. et al. PU.1 (Spi-1) and C/EBPa regulate the expression of the granulocyte-macrophage colony-stimuating factor receptor-α gene. Mol. Cell. Biol. 15, 5830-5845 (1995).
35. Zhang, D.-E., Hetherington, C. J., Chen, H. M. & Tenen, D. G. The macrophage transcription factor PU.1 directs tissue specific expression of the macrophage colony stimulating factor receptor. Mol. Cell. Biol. 14, 373-381 (1994).
36. Smith, L. T., Hohaus, S., Gonzalez, D. A., Dziennis, S. E. & Tenen, D. G. PU.1 (Spi-1) and C/EBPα regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood 88, 1234-1247 (1996).
37. Iwama, A. et al. Use of RDA analysis of knockout mice to identify myeloid genes regulated in vivo by PU.1 and C/EBPα. Nucl. Acids Res. 26, 3034-3043 (1998).
38. Zhang, D.-E. et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice. Proc. Natl Acad. Sci. USA 94, 569-574 (1997). First demonstration that targeted disruption of C/EBPα results in an earty granulocytic differentiation block.
39. Wang, X., Scott, E. W., Sawyers, C. L. & Friedman, A. D. C/ EBPα bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood 94, 560-571 (1999).
40. Timchenko, N. A., Wilde, M., Nakanishi, M., Smith, J. R. & Darlington, G. J. CCAAT/enhancer-binding protein a (C/EBPα) inhibits cell proliferation though the p21 (WAF-1/ CIP-1/SDI-1) protein. Genes Dev. 10, 804-815 (1996).
41. Wang, H. et al. C/EBPα arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol. Cell 8, 817-828 (2001).
42. Johansen, L. M. et al. C-myc is a critical target for C/EBPα in granulopoiesis. Mol. Cell. Biol. 21, 3789-3806 (2001).
43. Porse, B. T. et al. E2F repression by C/EBPα is required for adipogenesis and granulopoiesis in vivo. Cell 107, 247-258 (2001). Shows the important link between the ability of C/EBPα to inhibit the cell-cycle-promoting gene E2F and the ability to induce granulocytic differentiation.
44. Zon, L. I., Youssoufian, H., Mather, C., Lodish, H. F. & Orkin, S. H. Activation of the erythropoietin receptor promoter by transcription factor GATA-1. Proc. Natl Acad. Sci. USA 88, 10638-10641 (1991).
45. Timchenko, N. et al. Autoregulation of the human C/EBPα gene by stimulation of upstream stimulatory factor binding. Mol. Cell. Biol. 15, 1192-1202 (1995).
46. Chen, H. M. et al. PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene 11, 1549-1560 (1995).
47. Li, Y. et al. Regulation of the PU.1 gene by distal elements. Blood 98, 2958-2965 (2001).
48. Pedersen, T. A., Kowenz-Leutz, E., Leutz, A. & Nerlov, C. Cooperation between C/EBPα TBP/TFIIB and SWI/SNF recruiting domains is required for adipocyte differentiation. Genes Dev. 15, 3208-3216 (2001).
49. Zhang, P. et al. Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein α (C/EBPα) is critical for granulopoiesis. J. Exp. Med. 188, 1173-1184 (1998).
50. McKnight, S. L. McBindall: a better name for CCAAT/enhancer binding proteins? Cell 107, 259-261 (2001).
51. Felsher, D. W. & Bishop, J. M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199-207 (1999).
52. Schuster, C. et al. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. Blood 101, 655-663 (2003).
53. Sposi, N. M. et al. Cell cycle-dependent initiation and lineage-dependent abrogation of GATA-1 expression in pure differentiating hematopoietic progenitors. Proc. Natl Acad. Sci. USA 89, 6353-6357 (1992).
54. Strom, D. K. et al. Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J. Biol. Chem. 275, 3438-3445 (2000).
55. Bernardin, F. & Friedman, A. D. AML1 stimulates G1 to S progression via its transactivation domain. Oncogene 21, 3247-3252 (2002).
56. Metcalf, D., Lindeman, G. J. & Nicola, N. A. Analysis of hematopoiesis in max 41 transgenic mice that exhibit sustained elevations of blood granulocytes and monocytes. Blood 85, 2364-2370 (1995).
57. -/- mice: increased rate of myeloid proliferation and apoptosis. Leukemia 15, 103-111 (2001).
58. Metcalf, D. Hematopoietic regulators: redundancy or subtlety. Blood 82, 3515-3523 (1993).
59. Roberts, R. et al. Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature 332, 376-378 (1988).
60. Fairbairn, L. J., Cowling, G. J., Reipert, B. M. & Dexter, T. M. Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors. Cell 74, 823-832 (1993).
61. Just, U. et al. Upregulation of lineage specific receptors and ligands in multipotential prognitor cells is part of an endogenous program of differentiation. Growth Factors 9, 291-300 (1993).
62. Vaso, M. T. et al. Inhibition of hemetopoiesis by competitive binding of the transcription factor PU.1. Proc. Natl Acad. Sci. USA 91, 7932-7936 (1994).
63. Hu, M. et al. Multilineage gene expression precedes commitment in the hematopoietic system. Genes Dev. 11, 774-785 (1997).
64. Zhang, P. et al. PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood 96, 2641-2648 (2000).
65. Bennett, J. M. et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) cooperative group. Br. J. Haematol 33, 451-458 (1976). A landmark paper that established a classification system of AML on the basis of differentiation status.
66. Jordan, C. T. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia 16, 559-562 (2002).
67. Guan, Y. & Hogge, D. E. Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia 14, 2135-2141 (2000).
68. Perrotti, D. et al. BCR-ABL suppresses C/EBPα expression through inhibitory activity of hnRNP E2. Nature Genet. 30, 48-58 (2001). Describes yet another mechanism of inactivation of C/EBPα in AML - that involving the downregulation of C/EBPα through post-transcriptional mechanisms as the chronic (proliferative) phase transforms to acute leukaemia.
69. Grimwade, D. et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92, 2322-2333 (1998).
70. Preudhomme, C. et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 100, 2717-2723 (2002). Relates the status of C/EBPα mutations, with and without FLT3-ITD, to prognosis, and proposes a new classification of AML based on C/EBPα mutation status.
71. Miyoshi, H. et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl Acad. Sci. USA 88, 10431-10434 (1991).
72. Song, W. J. et al. Haploinsuficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nature Genet. 23, 166-175 (1999). Reports the haploinsufficiency of an important haematopoietic transcription factor that leads to a propensity to develop AML.
73. Osato, M. et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2αB gene associated with myeloblastic leukemias. Blood 93, 1817-1824 (1999). This study, along with reference 74, shows that AML1 could be involved in the pathogenesis of AML through a mechanism other than translocation, and that AML1 mutations were associated with a distinct differentiation subtype of AML.
74. o acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 98, 2862-2869 (2000).
75. Michaud, J. et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML): implications for mechanisms of pathogenesis. Blood 99, 1364-1372 (2002).
76. Ichikawa, H. et al. AML1 is required for megakaryocytic maturation in adult hematopoiesis. Blood 100, 130a (2003).
77. Leroy, H. et al. Unlike AML1, CBFβ is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes. Blood 99, 3848-3850 (2002).
78. Wang, Q. et al. The CBFβ subunit is essential for CBFα2 (AML1) function in vivo Cell 87, 697-708 (1996).
79. Sasaki, K. et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. Proc. Natl Acad. Sci. USA 93, 12359-12363 (1996).
80. Vegesna, V. et al. C/EBP-β C/EBP-δ, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk. Res. 26, 451-457 (2002).
81. Mueller, B. U. et al. PU.1 mutations are associated with acute myeloid leukemia. Blood 100, 998-1007 (2002).
82. Garrett-Sinha, L. A., Dahl, R., Rao, S., Barton, K. P. & Simon, M. C. PU.1 exhibits partial functional redundancy with Spi-B, but not with Ets-1 or Elf-1. Blood 97, 2908-2912 (2001).
83. Westendorf, J. J. et al. The t(8:21) fusion product, AML-1-ETO, associates with C/EBP-α, inhibits C/EBP-α-dependent transcription, and blocks granulocytic differentiation. Mol. Cell. Biol. 18, 322-333 (1998). Established that the mechanism of differentiation block induced by AML1-ETO involved inhibition of C/EBPα that is required for granulocyte differentiation.
84. Vangala, R. K. et al. The myeloid master regulator PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 101, 270-277 (2002).
85. Pabst, T. et al. Dominant negative mutations of CEBPα, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nature Genet. 27, 263-270 (2001). The first report of C/EBPα mutations in AML, this also describes a dominant-negative mechanism that could explain how mutation of one allele could inhibit the differentiation function of the other (wild-type) allele.
86. Gombart, A. F. et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein-α in myelodysplastic syndromes and acute myeloid leukemias. Blood 99, 1332-1340 (2002).
87. Wechsler, J. M. M. A., Anastasi, J., Karp, J. E., LeBeau, M. M. & Crispino, J. D. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down Syndrome. Nature Genet. 32, 148-152 (2002).
88. Visvader, J. E., Crossley, M., Hill, J., Orkin, S. H. & Adams, J. M. The C-terminal zinc finger of GATA-1 or GATA-2 is sufficient to induce megakaryocytic differentiation of an early myeloid cell line. Mol. Cell. Biol. 15, 634-641 (1995).
89. Weiss, M. J., Yu, C. & Orkin, S. H. Erythroid-cell-specific properties of transcription factor GATA-1 revealed by phenotypic rescue of a gene-targeted cell line. Mol. Cell. Biol. 17, 1642-1651 (1997).
90. Shimizu, R., Takahashi, S., Ohneda, K., Engel, J. D. & Yamamoto, M. In vivo requirements for GATA-1 functional domains during primitive and definitive erythropoiesis. EMBO J. 20, 5250-5260 (2001).
91. Pabst, T., Mueller, B. U., Harakawa, N., Zhang, D.-E. & Tenen, D. G. AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia. Nature Med. 7, 444-451 (2001).
92. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
93. Park, D. J. et al. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. J. Clin. Invest. 103, 1399-1408 (1999).
94. Truong, B. T. H. et al. CCAAT/enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. Blood 101, 1141-1148 (2003).
95. Duprez, E. A., Koch, H. & Tenen, D. G. C/EBPβ is an important target of PML-RARA during ATRA induced differentiation of APL cells. Blood 98, 833a (2001).
96. Laribee, R. N. & Klemsz, M. J. Loss of PU.1 expression following inhibition of histone deacetylases. J. Immunol. 167, 5160-5166 (2001).
97. Halmos, B. et al. Down-regulation and antiproliferative role of C/EBPα in lung cancer. Cancer Res. 62, 528-534 (2002).
98. + cells that mediate long-term engraftment of NOD/SCI mice by HIV vectors. Science 283, 682-686 (1999).
99. Elliott, G. & O'Hare, P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88, 223-233 (1997).
100. Schwarze, S. R., Ho, A., Vocero-Akbani, A. & Dowdy, S. F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569-1572 (1999).
101. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-Ras. Genes Dev. 15, 3243-3248 (2001).
102. Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 3, 730-737 (1997).
103. Miyamoto, T., Weissman, I. L. & Akashi, K. AML1-ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc. Natl Acad. Sci. USA 97, 7521-7526 (2000).
104. Collins, S. J., Ulmer, J. Purton, L. E. & Darlington, G. Multipotent hematopoietic cell lines derived from C/EBPα (-/-) knock out mice display macrophage-colony-stimulating factor, granulocyte-colony-stimulating factor, and retinoic acid-induced granulocytic differentiation. Blood 98, 2382-2388 (2001).
105. Zhang, P. et al. Induction of granulocytic differentiation by two pathways. Blood 99, 4406-4412 (2002).
106. Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
107. Higuchi, M. et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1, 75-87 (2002).
108. Traver, D., Akashi, K., Weissman, I. L. & Lagasse, E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 9, 47-57 (1998).
109. Guzman, M. L. et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98, 2301-2307 (2001).
110. Kogan, S. C. et al. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PML-RARα) to block neutrophil differentiation and initiate acute leukemia. J. Exp. Med. 193, 531-543 (2001).
111. Schimmer, A. D., Hedley, D. W., Penn, L. Z. & Minden, M. D. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood 98, 3541-3553 (2001).
112. Nichols, K. E. et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nature Genet. 24, 266-270 (2000).
113. Behre, G. et al. C-Jun is a JNK-independent coactivator of the PU.1 transcription factor. J. Biol. Chem. 274, 4939-4946 (1999).
114. Okuno, Y. et al. Differential regulation of the human and murine CD34 genes in hematopoietic stem cells. Proc. Natl Acad. Sci. USA 99, 6246-6251 (2002).
115. Christy, R. J., Kaestner, K. H., Geiman, D. E. & Lane, M. D. CCAAT/enhancer binding protein gene promoter: binding of nuclear factors during differentiation of 3T3-L1 preadipocytes. Proc. Natl Acad. Sci. USA 88, 2593-2597 (1991).
116. Legraverend, C., Antonson, P., Flodby P. & Xanthopoulos, K. G. High level activity of the mouse CCAAT/enhancer binding protein (C/EBPα) gene promoter involves autoregulation and several ubiquitous transcription factors. Nucl. Acids Res. 21, 1735-1742 (1993).
117. Zhang, D.-E., Burel, S. A., Zhou, L., Hethenngton, C. J. & Yuan, Y. AML1 and AML1 fusion protein AML1-ETO in myeloid gene regulation and leukemogenesis. Blood Cells Mol. Dis. 27, 368-376 (2001).
118. Romana, S. P. et al. The t(12;21) of acute lymphoblastic leukemia results in a TEL-AML1 gene fusion. Blood 85, 3662-3670 (1995).
119. Golub, T. R. et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 92, 4917-4921 (1995).
120. Li, Q. L. et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109, 113-124 (2002).
121. Flodby, P., Barlow, C., Kylefjord, H., Ahrlund-Richter, L. & Xanthopoulos, K. G. Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein-α. J. Biol. Chem. 271, 24753-24760 (1996).
122. Seagroves, T. N. et al. C/EBPβ but not C/EBPα, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. Genes Dev. 12, 1917-1928 (1998).
123. Zahnow, C. A., Younes, P., Laucirica, R. & Rosen, J. M. Overexpression of C/EBPβ-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. J. Natl Cancer Inst. 89, 1887-1891 (1997).
124. Nerlov, C. & Ziff, E. B. CCAAT/enhancer binding protein-alpha amino acid motifs with dual TBP and TFIIB binding ability co-operate to activate transcription in both yeast and mammalian cells. EMBO J. 14, 4318-4328 (1995).
125. Friedman, A. D. & McKnight, S. L. Identification of two polypeptide segments of CCAAT/enhancer binding protein required for transcriptional activation of the serum albumin gene. Genes Dev. 4, 1416-1426 (1990).